Aberdeen Group plc Buys 65,878 Shares of IQVIA Holdings Inc. $IQV

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aberdeen Group plc lifted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 91.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 137,843 shares of the medical research company's stock after acquiring an additional 65,878 shares during the period. Aberdeen Group plc owned approximately 0.08% of IQVIA worth $23,856,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. American National Bank & Trust acquired a new stake in shares of IQVIA in the 1st quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after buying an additional 131 shares during the period. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after buying an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new stake in IQVIA during the 1st quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 3.0%

Shares of NYSE:IQV traded up $5.5970 during midday trading on Friday, hitting $190.9870. The stock had a trading volume of 1,619,418 shares, compared to its average volume of 1,441,272. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The business's 50-day simple moving average is $173.70 and its 200-day simple moving average is $168.51. The company has a market cap of $32.47 billion, a P/E ratio of 27.64, a PEG ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period last year, the business earned $2.64 earnings per share. The firm's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Cowen restated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays raised their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Truist Financial raised their target price on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Citigroup restated a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Finally, Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.